Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cellular Products	17.52M	16.07M	13.56M
Cellular Products Growth	9.06%	18.51%	-
Other	510.00K	1.09M	420.00K
Other Growth	-53.21%	159.52%	-
Total	18.03M	17.16M	13.98M
Total Growth	5.11%	22.75%	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Taiwan	18.03M	17.16M	13.98M
Taiwan Growth	5.11%	22.75%	-
Total	18.03M	17.16M	13.98M
Total Growth	5.11%	22.75%	-

Source: S&P Global Market Intelligence.